PRMT6 increases cytoplasmic localization of p21CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agents
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Makoto Nakakido 1, * , Zhenzhong Deng 1, * , Takehiro Suzuki 2 , Naoshi Dohmae 2 , Yusuke Nakamura 1 , Ryuji Hamamoto 1 1 Section of Hematology/Oncology, Department of Medicine, The University of Chicago, MC2115, Chicago, IL 60637, USA 2 Biomolecular Characterization Unit, RIKEN Center for Sustainable Resource Science, Saitama 351–0198, Japan * These authors have contributed equally to this work Correspondence to: Ryuji Hamamoto, e-mail: rhamamoto@medicine.bsd.uchicago.edu Keywords: p21 CDKN1A , arginine methylation, PRMT6, subcellular localization, cancer chemoresistance Received: July 08, 2015 Accepted: August 12, 2015 Published: September 03, 2015 ABSTRACT p21 CDKN1A is known as a potent inhibitor of cyclin-dependent kinase (CDK), which regulates cell cycle in response to various stimuli, including DNA damage, on the p53-dependent manner. Here we demonstrate that protein arginine methyltransferase 6 (PRMT6) methylates p21 at arginine 156 and promotes phosphorylation of threonine 145 on p21, resulting in the increase of cytoplasmic localization of p21. The cytoplasmic presence of p21 makes cancer cells more resistant to cytotoxic agents. Our results indicate that PRMT6 appears to be one of the key proteins to dysregulate p21 functions in human cancer, and targeting this pathway may be an appropriate strategy for development of anticancer drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p21 in cancer: Intricate networks and multiple activities
Abbas, T., & Dutta, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2657 · Cited by 2,712 · cited 4×
“Three E3 ubiquitin ligase complexes, SCFSKP2 (SKP1-CUL1-SKP2), CRL4CDT2 (CUL4A or CUL4B-DDB1-CDT2) and APC/ CCDC20 poly-ubiquitinate p21, and promote the proteasomedependent proteolysis at specific cell cycle stages [2].”
BackgroundInfluentialThe p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
Waga, S., Hannon, G. J., Beach, D., & Stillman, B. (1994) · Nature · doi:10.1038/369574a0 · Cited by 1,655
Hayami, S., Kelly, J. D., Cho, H., Yoshimatsu, M., Unoki, M., Tsunoda, T., Field, H. I., Neal, D. E., Yamaue, H., Ponder, B. A. J., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25349 · Cited by 489 · cited 1×
“Cell cycle analysis was conducted as previously described [46–50].”
MethodSelf-citationRoninson, I. B. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00847-3 · Cited by 443 · cited 1×
“Cytoplasmic p21 protein is able to bind to and inhibit caspase 3, as well as the apoptotic kinases ASK1 and JNK [7–9].”
BackgroundCritical roles of non-histone protein lysine methylation in human tumorigenesis
Hamamoto, R., Saloura, V., & Nakamura, Y. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3884 · Cited by 376 · cited 1×
“Indeed, dysregulation of arginine and lysine methyltransferases have frequently been observed in human cancer [38–43], and these enzymes are now considered as emergent targets for anti-cancer drug development [14, 39, 44].”
BackgroundSelf-citation
Cited by
Shamloo, B., & Usluer, S. (2019) · Cancers · doi:10.3390/cancers11081178 · Cited by 336
“These post translational modifications increase cytoplasmic localization of p21, which results in more resistant cancer cells to cytotoxic agents [129].”
BackgroundHamamoto, R., Suvarna, K., Yamada, M., Kobayashi, K., Shinkai, N., Miyake, M., Takahashi, M., Jinnai, S., Shimoyama, R., Sakai, A., et al. (2020) · Cancers · doi:10.3390/cancers12123532 · Cited by 207
Self-citation
Metadata
- Authors
- Nakakido, M., Deng, Z., Suzuki, T., Dohmae, N., Nakamura, Y., & Hamamoto, R.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-09-03
- Volume
- 6
- Issue
- 31
- Pages
- 30957-30967
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2119123652
- Cited by
- 51
- References
- 5
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.